Jazz Pharmaceuticals plc (JAZZ) Stock
JAZZ Key Statistics
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
CEO: Renee D. Gala. Company website
JAZZ — Frequently Asked Questions
What is the JAZZ stock price today?
Jazz Pharmaceuticals plc (JAZZ) trades at $240.74, down 1.27% on the day, as of Sep 20, 2026 14:57 UTC.
What is Jazz Pharmaceuticals plc's market cap?
Jazz Pharmaceuticals plc has a market capitalisation of $15.12B, calculated from the live JAZZ share price and shares outstanding.
What is the P/E ratio of JAZZ?
JAZZ trades at a trailing P/E of 16.46, from earnings per share of $14.63 over the last twelve months.
How much revenue does Jazz Pharmaceuticals plc make?
Jazz Pharmaceuticals plc generated revenue of $4.60B over the trailing twelve months, which puts the stock at 3.29 times sales.
What is the 52-week range for JAZZ?
JAZZ has traded between $123.88 and $266.38 over the past 52 weeks, and the last price is 9.6% below that high.
Is Jazz Pharmaceuticals plc profitable?
Yes. Jazz Pharmaceuticals plc keeps 20.45% of revenue as net income over the trailing twelve months.
What is the analyst price target for JAZZ?
Wall Street analysts rate JAZZ Buy, with an average price target of $289.50, 20.3% above the current price.
What sector is Jazz Pharmaceuticals plc in?
Jazz Pharmaceuticals plc is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in IE.
Who is the CEO of Jazz Pharmaceuticals plc?
Renee D. Gala is the chief executive of Jazz Pharmaceuticals plc, which employs 2,890 people.
Where can I track JAZZ in real time?
QFI Terminal shows JAZZ with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See JAZZ live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open JAZZ in Terminal See plans